ArticleMed (New York, N.Y.)2021
Reduced blood-stage malaria growth and immune correlates in humans following RH5 vaccination.
Open access · hybridAbstract read
In one paragraph
Article in Med (New York, N.Y.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 97 papers.
0numbers the graph read from it
0cells of the map it votes in
97citing papers in PubMed
26.3field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
97 citing papers in PubMed, 161 citations in OpenAlex.
- Magnitude and durability of ProC6C-AlOH/Matrix-MHuman vaccines & immunotherapeutics · 2025Trial
- A Pfs48/45-based vaccine to block Plasmodium falciparum transmission: phase 1, open-label, clinical trial.BMC medicine · 2024Trial
- Safety and immunogenicity of BK-SE36 in a blinded, randomized, controlled, age de-escalating phase Ib clinical trial in Burkinabe children.Frontiers in immunology · 2022Trial
- Repeat controlled human malaria infection of healthy UK adults with blood-stageFrontiers in immunology · 2022Trial
- Antibodies from malaria-exposed Malians generally interact additively or synergistically with human vaccine-induced RH5 antibodies.Cell reports. Medicine · 2021Trial
- A dual-antigen mRNA-lipid polyplex vaccine elicits durable multistage immunity and sterile protection against malaria in mice.Acta pharmacologica Sinica · 2026Article
- Germinal Center Selection and Plasma Cell Differentiation.Immunological reviews · 2026Review
- Malaria serology for surveillance, insights into immunity, and vaccine development.Infection and immunity · 2026Review
- Identification of Novel Malaria Antigens Expressed on the Surface of RBCs Infected withVaccines · 2026Article
- Recent Advances, Bottlenecks, and Future Directions inVaccines · 2026Review
- Structure-guided design of a PfCyRPA-based vaccine against blood-stage malaria.EMBO molecular medicine · 2026Article
- Erythrocyte invasion in malaria: from molecular mechanisms to rational vaccines.Nature reviews. Microbiology · 2026Review
- Article
- B and T cell responses to pre-erythrocytic R21/Matrix-M and blood-stage RH5.1/Matrix-M malaria vaccines in endemic settings.Frontiers in immunology · 2026Article
- Bivalent virus-like particles expressing SPECT1 and CSP trigger pre-erythrocytic malaria immunity and protect against transgenicFrontiers in immunology · 2026Article
- Tfh2 and a subset of Tfh1 cells associate with antibody-mediated immunity to malaria.JCI insight · 2025Article
- Malaria vaccines: Current developments and immunological insights.New microbes and new infections · 2025Article
- Causal Approaches to Disease Progression Analyses.Epidemiology (Cambridge, Mass.) · 2025Article
- Diagnosis of Plasmodium falciparum malaria at very low parasitaemias using a commercially available LAMP assay and RDT.Transactions of the Royal Society of Tropical Medicine and Hygiene · 2025Article
- Development of clinical immunity to Plasmodium vivax following repeat controlled human malaria infection.Nature communications · 2025Article
37 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
50 authors at 12 institutions in 4 countries.
Angela M MinassianThe Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
Sarah E SilkThe Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
Jordan R BarrettThe Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
Carolyn M NielsenThe Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
Kazutoyo MiuraLaboratory of Malaria and Vector Research, NIAID/NIH, Rockville, MD 20852, USA.
Ababacar DioufLaboratory of Malaria and Vector Research, NIAID/NIH, Rockville, MD 20852, USA.
Carolin LoosThe Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.
Jonathan K FallonThe Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.
Ashlin R MichellThe Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.
Michael T WhiteDepartment of Parasites and Insect Vectors, Institut Pasteur, 25-28 Rue du Dr Roux, 75015 Paris, France.
Nick J EdwardsThe Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
Ian D PoultonThe Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
Celia H MittonThe Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
Ruth O PayneThe Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
Michael MarksCentre for Clinical Infection and Diagnostics Research, King's College London and Guy's & St Thomas' NHS Foundation Trust, Westminster Bridge Road, London SE1 7EH, UK.
Hector Maxwell-ScottCentre for Clinical Infection and Diagnostics Research, King's College London and Guy's & St Thomas' NHS Foundation Trust, Westminster Bridge Road, London SE1 7EH, UK.
Antonio Querol-RubieraCentre for Clinical Infection and Diagnostics Research, King's College London and Guy's & St Thomas' NHS Foundation Trust, Westminster Bridge Road, London SE1 7EH, UK.
Karen BisnauthsingCentre for Clinical Infection and Diagnostics Research, King's College London and Guy's & St Thomas' NHS Foundation Trust, Westminster Bridge Road, London SE1 7EH, UK.
Rahul BatraCentre for Clinical Infection and Diagnostics Research, King's College London and Guy's & St Thomas' NHS Foundation Trust, Westminster Bridge Road, London SE1 7EH, UK.
Tatiana OgrinaNIHR Wellcome Trust Clinical Research Facility, University Hospital Southampton NHS Foundation Trust, Faculty of Medicine, University of Southampton, Southampton SO16 6YD, UK.
Nathan J BrendishNIHR Wellcome Trust Clinical Research Facility, University Hospital Southampton NHS Foundation Trust, Faculty of Medicine, University of Southampton, Southampton SO16 6YD, UK.
Yrene ThemistocleousThe Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
Thomas A RawlinsonThe Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
Katherine J EllisThe Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
Doris QuinkertThe Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
Megan BakerThe Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
Raquel Lopez RamonThe Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
Fernando Ramos LopezThe Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
Lea BarfodThe Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
Pedro M FolegattiThe Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
Daniel SilmanThe Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
Mehreen DatooThe Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
Iona J TaylorThe Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
Jing JinThe Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
David PulidoThe Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
Alexander D DouglasThe Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
Willem A de JonghExpreSion Biotechnologies, SCION-DTU Science Park, Agern Allé 1, Hørsholm 2970, Denmark.
Robert SmithClinical BioManufacturing Facility, University of Oxford, Oxford OX3 7JT, UK.
Eleanor BerrieClinical BioManufacturing Facility, University of Oxford, Oxford OX3 7JT, UK.
Amy R NoeLeidos Life Sciences, Fredrick, MD, USA.
Carter L DiggsUSAID, 1300 Pennsylvania Ave. NW, Washington, DC 20004, USA.
Lorraine A SoissonUSAID, 1300 Pennsylvania Ave. NW, Washington, DC 20004, USA.
Rebecca AshfieldThe Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
Saul N FaustNIHR Wellcome Trust Clinical Research Facility, University Hospital Southampton NHS Foundation Trust, Faculty of Medicine, University of Southampton, Southampton SO16 6YD, UK.
Anna L GoodmanCentre for Clinical Infection and Diagnostics Research, King's College London and Guy's & St Thomas' NHS Foundation Trust, Westminster Bridge Road, London SE1 7EH, UK.
Alison M LawrieThe Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
Fay L NugentThe Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
Galit AlterThe Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.
Carole A LongLaboratory of Malaria and Vector Research, NIAID/NIH, Rockville, MD 20852, USA.
Simon J DraperThe Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
Jenner Institute · GBUniversity of Oxford · GBKing's College London · GBRagon Institute of MGH, MIT and Harvard · USVector Oncology (United States) · USGuy's and St Thomas' NHS Foundation Trust · GBUnited States Agency for International Development · USWellcome Trust · GBExpreS2ion Biotechnologies (Denmark) · DKInstitut Pasteur · FRLeidos (United States) · USUniversity of Southampton · GB
Funding
Host Immune Responses to Antigens of Malaria ParasitesZIAAI001020 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI LONG, CAROLE · 2009 to 2025
$13.6MMedical Research Council MC_UU_00004/05Medical Research Council MR/K025554/1Wellcome TrustWellcome Trust 106917/Z/15/ZWellcome Trust 108734/Z/15/ZWellcome Trust 209200/Z/17/Z
Abstract
backgroundDevelopment of an effective vaccine against the pathogenic blood-stage infection of human malaria has proved challenging, and no candidate vaccine has affected blood-stage parasitemia following controlled human malaria infection (CHMI) with blood-stage
methodsWe undertook a phase I/IIa clinical trial in healthy adults in the United Kingdom of the RH5.1 recombinant protein vaccine, targeting the
findingsThe RH5.1/AS01
conclusionsOur data provide a new framework to guide rational design and delivery of next-generation vaccines to protect against malaria disease.
fundingThis study was supported by USAID, UK MRC, Wellcome Trust, NIAID, and the NIHR Oxford-BRC.
Indexed as
MalariaMalaria, FalciparumMalaria VaccinesAdultHumansPlasmodium falciparumVaccinationVaccines, SyntheticMalaria VaccinesVaccines, Syntheticblood-stageCHMIclinical trialmalariaPlasmodium falciparumRH5systems serologyvaccine
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.